Immune Pharmaceuticals a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer has appointed G. John Mohr as senior vice president of business development and a member of the Immune executive committee. In this role, John Mohr will be responsible for overseeing alliance and business development activities for the company.
John Mohr has served in the pharmaceutical business for over twenty years in multiple functions including business development, strategic planning and marketing. Prior to joining Immune, he was managing director at the consulting firm BioAsset Advisors advising public and private companies on strategic partnering and licensing activities.
"We are pleased to have John join us to lead our business development and partnering activities," said Dr. Daniel Teper, CEO of Immune. "As a senior-level executive John has been involved in many significant transactions and brings valuable deal execution experience to our team. John is well acquainted with our Company's lead program, bertilimumab, and served as an advisor to Immune when at the time we acquired the license. John shares our vision for bertilimumab and will be leading our efforts to maximize strategic transactions for our entire portfolio."
John Mohr previously served as senior vice president with CV Therapeutics, a publicly traded drug company focused on innovative cardiovascular therapeutics, and he lead several major global transactions with Menarini and Astellas. In addition, he was instrumental in the $1.4 billion sale of the company to Gilead in 2009. Prior to that, he was the chief operating officer for Topigen Pharmaceuticals, a clinical stage company developing innovative therapeutics in the respiratory field. He was senior vice president with Atherogenics and President of Fournier Pharma US, where he delivered billion dollar deals with AstraZeneca and Abbott. John is a graduate of Drexel University in Finance and Accounting, a CPA and certified licensing executive.
"This is a pivotal time to join the company," said John Mohr. "In addition to the exciting opportunity with bertilimumab progressing in the clinic, Immune has several other valuable programs to offer for partnering. I look forward to adding value to Immune and working with the team."